POLY(A) POLYMERASE
The poly(A) polymerase GLD2 is required for spermatogenesis in Drosophila melanogaster
... short poly(A) tail remains untranslated or is ...time, poly(A) tail modifications occur outside the nucleus (Kim and Richter, ...transcriptional poly(A) tail adjustment contain two consensus ...
11
Poly(A) Polymerase and the Nuclear Poly(A) Binding Protein, PABPN1, Coordinate the Splicing and Degradation of a Subset of Human Pre-mRNAs
... terminal poly(A) tail as being important for a subset of intron excision events that follow cleavage and ...nuclear poly(A) binding protein, PABPN1, and poly(A) polymerase ...
13
<p>TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer</p>
... ing poly(ADP-ribose) polymerase family member 16 (PARP 16), PIN2/TERF1-interacting telomerase inhibitor 1 (PINX1), intracellular hyaluronan-binding protein 4 (HABP4), cyto- chrome P450 1A1 (CYP1A1), ...
14
Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach
... many poly(ADP-ribose) polymerase (PARP) inhibitors have been enrolled in clinical trials as a combination therapy for several types of cancer, and many of these were licensed by the Food and Drug ...
13
Treatment of breast cancer 2 (BRCA2) mutant follicular dendritic cell sarcoma with a poly ADP ribose polymerase (PARP) inhibitor: a case report
... Due to the finding of a BRCA2 mutation, it was decided to treat with the combination of carboplatin and a poly ADP-ribose polymerase (PARP) inhibitor. A compas- sionate supply of veliparib was sought. ...
5
Update on Poly ADP ribose polymerase inhibition for ovarian cancer treatment
... Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients ...
18
Activation of the Poly(ADP-Ribose) Polymerase Pathway in Human Heart Failure
... Poly(ADP-ribose) polymerase (PARP) activation has been implicated in the pathogenesis of acute and chronic myocardial dys- function and heart ...of poly-ADP ribosylated ...
10
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
... of poly(ADP-ribose) polymerases (PARPs), which play a key role in DNA damage/repair pathways, have been developed as antitumor agents based on the concept of synthetic ...
14
Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells
... and poly (ADP-ribose) polymerase (PARP) is a substrate of caspase-3 protease activity and its processing is usu- ally associated with apoptotic cell ...
12
CYTOTOXICITY AND IN SILICO STUDIES OF ANETHOLE IN TRIPLE NEGATIVE BREAST CANCER CELLS
... as poly-ADP-ribose and insulin like growth factor receptor were investigated in the present ...namely poly ADP-ribose polymerase (PARP) and insulin like growth factor receptor ...
6
QSAR, Docking and Invitro Antioxidant Activity Study of Novel Chromone Derivatives
... The Eq.2 and 4 from AM1 and PM3, semi empirical cal- culations reveal Hardness cause the inhibitory activi- ty.Higher values of Hardness is responsible for higher inhi- bitory activity nature for poly [ADP-ribose] ...
10
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy
... and poly(ADP-ribose) polymerase (PARP) inhibitors have known activity in advanced ovarian cancer, the effect of combined therapy against EGFR and PARP in this population has not been ...
8
Defective DNA repair mechanisms in prostate cancer: impact of olaparib
... aggressiveness. Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair mechanisms and represent a valid target for new ...
6
<div>Emerging treatment options for ovarian cancer: focus on rucaparib</div>
... Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are an exciting class of anticancer drugs, which have revolutionized the management of BRCA mutant/homologous recombination-deficient ...
12
<p>Role of pseudohypoxia in the pathogenesis of type 2 diabetes</p>
... Abstract: Type 2 diabetes is caused by persistent high blood glucose, which is known as diabetic hyperglycemia. This hyperglycemic situation, when not controlled, can overproduce NADH and lower nicotinamide adenine ...
8
Olaparib in the management of ovarian cancer
... a poly(ADP-ribose) polymerase (PARP) inhibitor, capitalizes on this concept and is the first drug in its class approved for patients with ovarian ...
9
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
... as poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, where early studies of olaparib showed response rates of 69% in those with platinum-sensitive disease, compared with 45% and 23% in the ...
14
An update on PARP inhibitors for the treatment of cancer
... of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation–related ...
10
Sulfur mustard induces expression of metallothionein-1A in human airway epithelial cells
... transcriptase poly- merase chain reaction results, confirmed by quantitative real- time reverse transcriptase polymerase chain reaction, indicate that expression of MT-1A at the mRNA level was significantly ...
7
Synthesis of DNA and Poly(Adenosine Diphosphate Ribose) in Normal and Chronic Lymphocytic Leukemia Lymphocytes
... and poly-(adenosine diphosphate ribose) (poly[ADPR]) immediately after isolation and on successive days following their treatment with phytohemagglutinin ...
9